Product Usage: Our peptides are for in vitro research purposes only and are not for human consumption. The statements made within the website have not been evaluated by the USA Food and Drug Administration.
BPC-157 in Plain English
BPC-157 is a laboratory-made peptide made from a short chain of 15 amino acids. Amino acids are the small building blocks that make up peptides and proteins. The name “BPC” comes from “Body Protection Compound,” a term used in early research papers for a substance studied in connection with proteins found in gastric juice. BPC-157 is the specific 15-amino-acid sequence most often discussed in that research.
The compound became a research topic in the early 1990s through work led by Professor Predrag Sikiric and colleagues at the University of Zagreb in Croatia. Early papers described a newly identified gastric-juice peptide and later focused on the shorter sequence now called BPC-157. Since then, researchers have examined its chemistry, stability, and behavior in laboratory, cell, tissue, and animal models. Most of the published evidence remains preclinical, meaning it does not establish approved medical use, safety, or effectiveness.
Today, BPC-157 is mainly discussed as an investigational research peptide. Scientists study how its sequence behaves, how it can be identified and measured, and how experimental results differ across research models. This page focuses on the product’s identity, specifications, testing documents, and research background. It does not provide instructions for human or animal use.
Key Takeaways
- BPC-157 is a synthetic research peptide made from 15 amino acids.
- Most published biological research is preclinical and comes from laboratory, tissue, and animal models.
- COA, HPLC, and MS documents answer different questions about batch records, purity, and identity.
- Analytical testing does not establish biological activity, safety, effectiveness, sterility, or approved use.
- This product is supplied for laboratory research only and is not for human or animal use.
Why Do Researchers Study BPC-157?
Researchers continue to examine BPC-157 because it is a short, defined peptide sequence that can be studied across several types of experimental systems. Published work has explored its chemical properties, stability, analytical identification, cell signaling, cell movement, connective-tissue models, vascular models, and gastrointestinal models.
Interest in a compound does not prove that it is safe or effective. It means researchers have identified questions worth investigating. For BPC-157, the major unresolved questions include how consistently it can be formulated, how it behaves in different biological systems, whether findings can be independently repeated, and whether high-quality human evidence will ever support broader conclusions.
BPC-157 5mg — Package Overview
BPC-157 5 mg 5 Vials is supplied for laboratory research only. The package contains 5 vials with 5 mg per vial. The total price is $110.15, or $22.03 per vial.
- Verification: current COA, HPLC, and MS documents are available on this product page.
- Purity context: ≥99% listed purity; current COA shows 99.01% purity by HPLC.
- Shipping: $14.99 USPS Priority shipping is standard; see the shipping policy.
- Intended use: research use only; not for human or animal use.
Quick Facts & Key Specifications
This table gives the main product details, package format, and available testing documents at a glance.
| Product | BPC-157 10mg 5 Vials |
|---|---|
| SKU | bpc-157-10mg-5-vials-1 |
| Categories | BPC 157; Peptides; Research Chemical |
| Tags | Body Protection Compound 157; BPC; BPC157; peptides |
| Package format | 5 vials; 10mg per vial; lyophilized peptide material |
| Price context | $198.25 package total; $39.65 per vial |
| Purity context | ≥99% listed purity; current COA shows 99.01% purity by HPLC |
| Identity / sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Verification | COA, HPLC, and MS documentation displayed on this page and retained in product tabs |
| Intended use | Laboratory research only; not for human or animal use |
A scannable research-only summary of package details and analytical-document availability.
Package5 vials • 10mg per vialPrice context$39.65 per vialPurity context≥99% listed • COA: 99.01%by HPLCDocumentsCOA + HPLC + MS visible onpageBoundaryLaboratory research onlySKUbpc-157-10mg-5-vials-1Categories: BPC 157 • Peptides • Research ChemicalTags: Body Protection Compound 157 • BPC • BPC157 • peptidesUS Chem Labs • BPC-157 research product documentation
What Is This Peptide?
Because it is freeze-dried, the material may look like a fine powder, a light cake, or a small compact puck inside the vial. These differences can happen during normal freeze-drying. Appearance alone cannot confirm identity or purity, so the batch documents should also be reviewed. For more background, see the Peptide Storage and Handling Research Guide.
History & Research Background
BPC-157 is the 15-amino-acid sequence GEPPPGKPADDAGLV. Research on the compound began in the early 1990s with scientists at the University of Zagreb, including Professor Predrag Sikiric and his colleagues. Their early work connected the sequence with a larger peptide described in gastric-juice research. Later studies examined BPC-157 in a wide range of laboratory, cell, tissue, and animal models.
Most published studies are preclinical. That means they were conducted in laboratory systems or animal models rather than in large, controlled human trials. These findings do not prove safety, effectiveness, or an approved medical use.
Research Snapshot: Current State of Research
Most BPC-157 research has been done in laboratory, cell, tissue, and animal models. Reviews continue to point out important unanswered questions, including how the compound is formulated, how it moves through a biological system, how toxicity should be measured, and whether results can be repeated in well-controlled human studies.
Dominant evidence type
Most published evidence comes from cell, tissue, and animal-model research. Human evidence remains too limited to establish general safety or effectiveness.
Frequently studied themes
Peptide chemistry, nitric-oxide and vascular signaling, cell movement, connective-tissue models, gastrointestinal models, and analytical testing.
Evidence boundary
COA, HPLC, and MS records support identity, purity, and batch review. They do not demonstrate biological activity, safety, or effectiveness.
- PubMed PMID 21030672 — BPC 157 tendon-outgrowth, cell-survival, and cell-migration research record.
- PubMed PMID 23755725 — BPC 157 and nitric-oxide-system research context.
- PubMed PMID 29998800 — BPC 157 and angiogenic growth-factor context.
- PubMed PMID 34267654 — BPC 157 wound-healing research context.
- PubMed PMID 30915550 — review of BPC-157 in musculoskeletal soft-tissue research, emphasizing that most evidence comes from small-animal models.
- PubMed PMID 40005999 — 2025 literature and patent review discussing proposed biological activities and the lack of sufficient comprehensive clinical evidence.
- PubMed PMID 40789979 — 2025 review of musculoskeletal research noting broad preclinical findings but extremely limited human data.
- PubMed PMID 42198317 — 2026 review focused on formulation, pharmacokinetic, and translational-development barriers.
Research Models & Proposed Pathways
Researchers have examined several possible pathways and measurable laboratory outcomes. These are proposed explanations or observations from specific models—not confirmed medical mechanisms.
| Research area | Examples of studied endpoints | Interpretive boundary |
|---|---|---|
| Vascular and endothelial models | VEGF-related signaling, endothelial responses, nitric-oxide pathways, and vascular organization in experimental injury models | Mechanistic and model-specific evidence; not proof of a therapeutic vascular effect in humans |
| Cell and tissue-repair models | Cell survival, migration, fibroblast behavior, collagen organization, and tissue morphology | Laboratory endpoints do not independently establish a clinical outcome |
| Musculoskeletal models | Tendon, muscle, ligament, and junction-healing observations in animal or ex vivo systems | Most published evidence is preclinical and may not translate to humans |
| Gastrointestinal models | Mucosal integrity, ulcer-related experimental injury, and cytoprotection hypotheses | Historical and preclinical research; not approved treatment guidance |
| Nervous-system models | Behavioral, neurochemical, injury, and brain–gut-axis endpoints in animals | Exploratory evidence with substantial translational uncertainty |
Evidence Level & Research Limitations
BPC-157 remains investigational. Many papers describe preclinical experiments, but reliable human evidence is still very limited. Researchers still need better information on standardized formulations, how the compound moves through a biological system, formal toxicology, independent replication, and controlled clinical trials.
Where the published evidence is concentrated—and what remains unresolved.
Chemical identitySequenceFormula and massHPLC / MS context
Preclinical evidenceCell modelsTissue modelsAnimal modelsLargest evidence category
Human evidenceSmall pilot reportsLimited standardizationInsufficient validation
Still neededControlled trialsReplication + toxicology
Preclinical findings can justify further research.They do not establish approved human use, safety, or effectiveness.
Key limitations to disclose
- Many frequently cited findings originate from animal models or a limited number of research groups.
- Experimental preparation, route, model, endpoint, and study design vary across publications.
- Human pharmacokinetic, toxicology, interaction, and long-term safety data remain incomplete.
- Analytical purity does not establish sterility, endotoxin status, clinical suitability, efficacy, or safety.
- Absence of reported adverse events in small studies is not evidence of broad safety.
Common Misconceptions
| Misconception | More accurate interpretation |
|---|---|
| “A 99% HPLC result proves the material will produce a biological effect.” | HPLC supports chromatographic purity under the reported method. It does not establish identity by itself, biological activity, sterility, safety, or efficacy. |
| “A positive animal study means the same outcome will occur in humans.” | Animal studies can identify research signals, but species differences, model design, exposure, and endpoints limit translation. |
| “A proposed pathway is a confirmed mechanism.” | Pathway findings may be model-dependent and require independent replication and clinical validation. |
| “No major adverse event reported means the compound is proven safe.” | Small or uncontrolled studies cannot reliably detect uncommon, delayed, interaction-related, or long-term risks. |
| “A COA is the same as regulatory approval.” | A COA is a batch document. It is not an approval, clinical evaluation, or authorization for human or animal use. |
Future Research Directions
Future research would need standardized materials, validated testing methods, stability studies, formal toxicology, independent replication, and well-designed controlled trials. Until those gaps are addressed, BPC-157 should be described as an investigational research peptide—not an established medical product.
Testing & Verification: HPLC, LC-MS/MS, COA, and Why Both Matter
These tests answer different questions. A Certificate of Analysis (COA) summarizes the batch record, HPLC helps show purity, and MS or LC-MS/MS helps confirm whether the measured mass matches the expected peptide.
COA
Connects the product record to a batch, reported purity, and document date.
HPLC
Shows separated peaks under the stated method and gives context for the listed purity figure.
LC-MS/MS / MS
Supports identity review by comparing mass-based evidence against the expected peptide.
Why both matter: purity and identity are different. HPLC helps show how much of the sample matches the main measured component. MS helps confirm whether the material has the expected mass. Reviewing both with the COA gives a more complete batch record.
Quality Assurance & Batch Documentation
The current batch documents are collected here for easy review. The same PDFs are also available in the COA, HPLC, and MS product tabs.
| Document | Current version | What it supports |
|---|---|---|
| COA | USCL 070626 | Lot-level quality-control and purity documentation; current COA shows 99.01% purity by HPLC. |
| HPLC | USCL 073125 | Chromatographic purity review and peak-profile context for the listed batch record. |
| MS | USCL 070626 | Mass-spectrometry identity-support documentation for the named peptide material. |
BPC 157 5 mg 5 Vials Certificate of Analysis — USCL 070626
Lot-level quality-control and purity documentation; current COA shows 99.01% purity by HPLC. The PDF is embedded below and retained in the product tabs for quick access.
BPC 157 5 mg 5 Vials HPLC Chromatogram — USCL 073125
Chromatographic purity review and peak-profile context for the listed batch record. The PDF is embedded below and retained in the product tabs for quick access.
BPC 157 5 mg 5 Vials Mass Spectrometry Document — USCL 070626
Mass-spectrometry identity-support documentation for the named peptide material. The PDF is embedded below and retained in the product tabs for quick access.
Complete Technical Specifications
| Common name | BPC-157 |
|---|---|
| Alternative names | Body Protection Compound-157; Pentadecapeptide BPC-157 |
| Compound type | Synthetic research peptide |
| Amino-acid sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Amino acid length | 15 amino acids |
| CAS number | 137525-51-0 |
| Molecular formula | C₆₂H₉₈N₁₆O₂₂ |
| Molecular weight | 1,419.53 g/mol |
| PubChem CID | 9941957 |
| Appearance | White to off-white lyophilized peptide powder or compact cake, depending on freeze-drying conditions. |
| Storage context | Store refrigerated at 2–8°C unless product label, COA, or laboratory protocol specifies otherwise; protect from light, moisture, and unnecessary temperature cycling. |
Educational Insights: Understanding Peptide Quality
Peptide quality cannot be judged by one number alone. A complete review considers identity, purity, batch records, documentation, storage, and handling.
Purity is useful, but not complete
A high HPLC purity result is useful, but it should be reviewed together with the chromatogram, COA, and MS document. Purity alone does not confirm the product name, batch history, labeling, storage, or handling.
Lyophilized format and handling context
Lyophilization is a controlled freeze-drying process that removes water and leaves the peptide in a dry form. In laboratory work, factors such as the solvent, container, concentration, and buffer can affect how the material dissolves. This is general research context, not use guidance.
Documentation workflow
A simple review process is: confirm the product and batch, read the COA, look at the HPLC chromatogram, review the MS document, and save the records with the laboratory files.
Frequently Asked Questions
What is BPC-157 5 mg 5 Vials?
BPC-157 5 mg 5 Vials is a research peptide product containing five 5mg lyophilized BPC-157 vials for qualified laboratory research only.
What is the amino-acid sequence of BPC-157?
BPC-157 is commonly listed as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a 15-amino-acid peptide sequence.
What PubChem identifier is listed for BPC-157?
PubChem lists BPC-157 as Compound CID 9941957; the product specification table links to the PubChem compound record.
Which batch and testing documents are available?
The current page shows a COA, an HPLC chromatogram, and an MS document for the listed BPC-157 5mg product record.
Why is HPLC important when reviewing a peptide?
HPLC separates compounds under a stated method and provides chromatographic purity context for the reported purity figure.
Why is LC-MS/MS or MS important for peptide identity?
Mass-based testing supports identity review by comparing measured mass or fragmentation evidence with the expected peptide identity.
Why are both HPLC and MS useful?
They answer different quality questions: HPLC supports purity context, while MS or LC-MS/MS supports identity context.
Why is a batch-specific COA important?
A batch-specific COA ties the product record to a particular lot, test date, and document set for laboratory recordkeeping.
How is BPC-157 supplied for research?
This product is supplied as lyophilized peptide material in five sealed 5mg research vials.
Why are research peptides freeze-dried?
Research peptides are often freeze-dried through a process called lyophilization. Removing water under controlled conditions creates a dry material that is easier to store, document, and handle in a laboratory setting.
Can analytical documents predict a biological result?
No. COA, HPLC, and MS documents support identity, purity, and batch-record review; they do not establish biological outcomes or use guidance.
Does this product page provide dosing or human-use guidance?
No. The page is research-only and does not provide dosing, clinical, diagnostic, veterinary, or human-use guidance.
Is BPC-157 supported by human clinical trials?
Human evidence remains limited. Most published biological findings come from cell, tissue, and animal models, and current evidence is insufficient to establish general clinical safety or effectiveness.
What does “preclinical” mean?
Preclinical research includes laboratory, cell, tissue, and animal studies conducted before adequate controlled human clinical validation.
Does a proposed mechanism prove that BPC-157 works?
No. A proposed signaling pathway or model-specific mechanism is a research hypothesis or experimental observation and does not independently establish a clinical result.
What are the main gaps in BPC-157 research?
Frequently cited gaps include standardized formulations, validated pharmacokinetics, formal toxicology, independent replication, controlled human trials, and long-term safety data.
Selected Scientific References
These references provide research context and should be read with attention to study type, model, authorship, limitations, and publication date.
- PMID 17657443 — early pharmacological review and sequence description.
- PMID 20388964 — angiogenesis-related observations in muscle and tendon models.
- PMID 23782145 — review of vascular research themes.
- PMID 30915550 — musculoskeletal soft-tissue research review.
- PMID 40005999 — 2025 literature and patent review.
- PMID 40789979 — 2025 review emphasizing the gap between preclinical and human evidence.
- PMID 42198317 — 2026 review of formulation and translational barriers.
- PubChem CID 9941957 — compound identity, sequence, formula, and molecular-weight record.
A citation shows that a paper exists; it does not by itself establish that its conclusions are correct, independently replicated, clinically applicable, or relevant to a particular batch of research material.
Editorial responsibility: USChem Labs Editorial Team
Technical review: Product specifications and batch documents reviewed against the records displayed on this page.
Last reviewed: August 2026
